nimotuzumab

Product Name: nimotuzumab
CAS No.: 828933-51-3
Chemical Name: nimotuzumab
Synonyms: nimotuzumab;Research Grade Nimotuzumab(DHB86914)
CBNumber: CB42498825
Formula Weight: 0
MOL File: Mol file

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

N-Bromosuccinimide Price

Biosynth Carbosynth

Product number: BN165591
Product name: Nimotuzumab
Packaging: 1mg
Price: $600
Updated: 2021/12/16

More

Less

nimotuzumab Chemical Properties,Usage,Production

Description

Overexpression of epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase, is prevalent in malignant tumors of epithelial origin and is especially common in breast, head and neck, colon, and lung cancer. With EGFR overexpression, prognosis is poor due to associated tumor invasion, metastasis, enhanced angiogenesis, and resistance to chemotherapy; thus, modulation of EGFR-mediated signaling is an attractive target for intervention. Small-molecule kinase inhibitors (gefitinib and erlotinib) and a monoclonal antibody (cetuximab) specific for EGFR are in clinical evaluation, but treatment cessation due to development of severe acne-like rash is common with these EGFR antagonists. Notably, nimotuzumab, a humanized form of the murine IgG2a monoclonal antibody that has been launched in India for treatment of head and neck cancers overexpressing EGFR, demonstrates clinical efficacy devoid of the rash toxicity. .

Originator

Center for Molecular Immunology (Cuba)

brand name

BioMab EFGR, Theraloc

nimotuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

nimotuzumab Suppliers

China 15 United States 3 Global 18

NCE Biomedical Co.,Ltd.

Tel: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax: +86-27-87599188
Country: China
ProdList: 1493
Advantage: 55

SPIRO PHARMA

Tel
Fax: -
Email: eric_feng1954@126.com
Country: China
ProdList: 9248
Advantage: 55

Shanghai EFE Biological Technology Co., Ltd.

Tel: 021-65675885 18964387627
Fax: 021-65675885
Email: info@efebio.com
Country: China
ProdList: 9806
Advantage: 58

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8012
Advantage: 62

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10424
Advantage: 58

Abmole Bioscience Inc.

Tel: 021-50967598 02150967598
Email: sales@abmole.cn
Country: China
ProdList: 4494
Advantage: 58

Jiangxi ravel Biotechnology Co.,Ltd

Tel: 400-880-2824; 13184580281
Fax: 400-880-2824
Email: hj@ruiweier.cn
Country: China
ProdList: 2737
Advantage: 58

Hubei Kele Fine Chemical Co., Ltd

Tel: 027-59101668 19945030958
Fax: 027-59101668
Email: 2881924765@qq.com
Country: China
ProdList: 7890
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604862
Email: products@biolabreagent.com
Country: China
ProdList: 9818
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 5821
Advantage: 58

Nanjing Shizhou Biology Technology Co.,Ltd

Tel: 025-85560043 15850508050
Fax: 025-85563444
Email: cindy.huang@synzest.com
Country: China
ProdList: 12000
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 13823398779 18670069958
Email: 3062105966@qq.com
Country: China
ProdList: 3262
Advantage: 58

Olix (Shanghai) Pharmaceutical Technology Co., Ltd

Tel: 17316404525
Email: 209533805@qq.com
Country: China
ProdList: 9731
Advantage: 58

Wanxin Biotechnology (Jiaxing) Co., LTD

Tel: 0573-83568680 18057391398
Email: 3956524501@qq.com
Country: China
ProdList: 1442
Advantage: 58

828933-51-3, nimotuzumabRelated Search:

Follicle stimulating hormone Secukinumab Daratumumab OMALIZUMAB Dulaglutide Trastuzumab emtansine Ranibizumab palivizumab Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Eculizumab Aflibercept abciximab Matuzumab ticilimumab tremelimumab CNTO 148 Vedolizumab Avelumab belimumab

nimotuzumab

Research Grade Nimotuzumab(DHB86914)

828933-51-3

828933-61-3